Molecular calculations on ligand-protein and protein-protein interactions by quantum chemical methods
MOLECULAR CALCULATIONS ON LIGAND-PROTEIN AND PROTEIN-PROTEIN INTERACTIONS BY MOLECULAR DYNAMICS SIMULATIONS AND QUANTUM CHEMICAL CALCULATIONS Peter Wolschann,Institute of Theoretical Chemistry, University of Vienna, Währinger
Straße 17, 1090 Wien, Tel.: +43 (1) 4277 52772, Fax: +43 (1) 4277 9527,
Project Progress Report: Quantum chemical calculations on the interaction of ligands with
proteins have been performed on several systems, in order to gain knowledge about the
applicability of various methods on particular problems.
Quantum chemical calculations based on ab initio and density functional theory (DFT)
methods have been applied to analyze detailed local interactions in proteins or between
protein and ligands. To describe these interactions, like hydrogen bonding or stacking of
aromatic rings, or hydrophobic Van der Waals interactions accurately, more precise quantum
chemical methods have to be applied. Various methods were tested for ligand protein
(peptide) interactions: In one of these this studies, the subtle interaction between individual
residues from the HIV-1 reverse transcriptase (RT) allosteric binding site and an inhibitor, S-
3-ethyl-7-fluoro-4-isopropoxy-carbonyl-3,4-dihydro-quinoxalin-2(1H)-one, was investigated
by using high-level quantum chemical calculations (MP2, M06-2X and B3LYP) with the
following basis sets: 6-31G(d), 6-31G(d,p), 6-311G(d), and 6-311G(d,p). The results obtained
indicate that the interaction between the inhibitor and Lys101 is the most important for the
binding. The interactions between ligands and the surrounding binding site depend on
different contributions of individual amino acids. The determination of these particular
interaction energies is sensitive to the model used, i.e. which part of the amino acids has been
taken into account and which terminating procedure has been applied. The results show that
even systems where the amide bond is cut and capped with hydrogen atoms can be used as
reliable models for estimating the individual interaction energies. Furthermore, the interaction
energies of GW420867X in wild-type and Lys101Glu mutant are also investigated in order to
explain the loss of GW420867X’s activity in Lys101Glu mutant. The results have been
In a study on the interaction of the enzyme enoyl-ACP reductase from Mycobacterium
Tuberculosis with isoniazid derivatives the interaction energies in the binding pocket were
calculated using quantum chemical calculations (MP2/6-31G(d)).
Structure optimization and calculations of partial charges of series of ligands have been
carried out for various systems of biological and medicinal relevance: Arylamides as novel
inhibitors of the enoyl-ACP reductase from Mycobacterium tuberculosis, tryptamine
derivatives at NMAD, 5HT1A and 5HT2A receptors, Huperzine A and Galanthamine binding to
Acetylcholinesterase, and screening by a series of natural products to the Epidermal Growth Factor
Receptor in a Tyrosine Kinase Domain. About all these investigations papers have been
already published, or have been submitted, or are in preparation.
Extensive preliminary calculations were performed on inhibitors for voltage-gated ion
channels, in particular Ca2+ and K+ ion channels. These data are used for docking and MD
studies on the open and the closed forms of these channels.
For the quantum chemical calculations the program package GAUSSIAN09 was used
throughout. In this software package several ab initio methods (HF, MP2) and density
functionals (BLYP, B3LYP, M06-2X) with a large number of different basis sets are
included. Also the ONIOM method is implemented in this program package. The Docking
procedures as well as the Molecular Dynamics simulations were carried out on local clusters
using AMBER and GROMACS. Up to now both Molecular Dynamics programs are not
available at the VSC. Moreover, GAUSSVIEW as support program for the installation
GAUSSIAN09 would be necessary. Publications
A. Punkvang, P. Sarparpakorn, S. Hannongbua, P. Wolschann, P. Pungpo
Elucidating Drug-Enzyme Interactions and Their Structural Basis for Improving the Affinity and Potency of Isoniazid and Its Derivatives Based on Computer Modeling Approaches Molecules 15, 2791-2813 (2010)
A. Punkvang, P. Saparpakorn, S. Hannongbua, P. Wolschann, H. Berner, P. Pungpo
Insight into Crucial Inhibitor-Enzyme Interaction of Arylamides as Novel Direct Inhibitors of the Enoyl ACP Reductase (InhA) from Mycobacterium Tuberculosis: computer-aided molecular design Mh.Chem. 141, 1029-1041 (2010)
A. Punkvang, P. Sarparpakorn, S. Hannongbua, P. Wolschann, P. Pungpo
Investigating the Structural Basis of Arylamides to Improve Potency against M. Tuberculosis Strain through Molecular Dynamics Simulations
Europ. J. Med. Chem. 45, 5585-5593 (2010)
Nareenart. , P. Wolschann, S. Hannongbua
Binding of Huperzine A and Galanthamine to Acetylcholinesterase, Based on ONIOM Method Nanomedicine: Nanotechnology, Biology, and Medicine
P. Saparpakorn, P. Wolschann, A. Karpfen, P. Pungpo, S. Hannongbua
Systematic investigation on the methodology in the binding of GW420867X as NNRTI by using quantum chemical calculations
M. L. Berger, R. Palangsuntikul, P. Rebernik, P. Wolschann, H. Berner
Screening of 64 tryptamine derivatives at NMDA, 5HT2A and 5HT1A receptors: a comparative binding and modeling study
R. Palangsuntikul, H. Berner., M. Berger, P. Rebernik, P. Wolschann
Holographic Quantitative Structure-Activity Relationships of Tryptamine Derivatives at NMDA, 5HT1A and 5HT2A Receptors
sprzyjaj¹ eliminacji anestetyku z tkanek i szybszemu towarzysz¹cych zniesieniu przewodnictwa nerwowego przechodzeniu do krwioobiegu, a wiêc akumulacji we na danym obszarze takich jak np. mrowienie wargi. Mog¹ one bowiem wywo³aæ lêk u dziecka i przyczyniæ W przypadku zabiegów chirurgicznych zmniejszaj¹ siê do utraty zaufania do lekarza, który nie uprzedzi³ one tak¿e krwawienie
Objectives 1. To encourage development of a sustainable schistosomiasis control programme in To reach at least 75% of school-age children and other high-risk groups with chemotherapy - praziquantel and albendazole. Reduce schistosomiasis-related morbidity in high risk groups. Reduce prevalence and intensity of schistosomiasis infections. Reduce burdens due to intestinal helminths in the targ